Back to ULGX
Urologix Regains NASDAQ Compliance With Minimum Shareholders' Equity Requirement

MINNEAPOLIS, July 18, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today it has received a letter of determination from The Nasdaq Stock Market ("NASDAQ") confirming that the Company has regained compliance with Listing Rule 5550(b)(1) requiring a minimum shareholders' equity of $2.5 million. The determination was received from NASDAQ after the Company reported the completion of the sale of 5,200,000 shares of the Company's common stock pursuant to an underwritten public offering. Urologix remains subject to the NASDAQ continued listing requirements.

"We are very pleased with NASDAQ's decision. We believe that the continued listing of our common stock on The NASDAQ Capital Market is in the best interests of our shareholders as we have completed the underwritten public offering that enabled us to meet NASDAQ's shareholders' equity standard," said Stryker Warren, Jr., Chief Executive Officer.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH).  Urologix' Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort.  The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families.  The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms.  Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license.  All other trademarks are the property of Urologix.

The Urologix, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7867

CONTACT: Brian J. Smrdel
         Chief Financial Officer
         (763) 475-7696

Urologix, Inc. Logo

Back to ULGX
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki